MAM
DFTX

Meeder Asset Management’s Definium Therapeutics DFTX Stock Holding History

Meeder Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.67K Buy
+353
New +$5.99K ﹤0.01% 780
2021
Q4 		– Sell
-140
Closed -$4K – 1876
2021
Q3 		$4K Buy
+140
New +$6.05K ﹤0.01% 2011

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meeder Asset Management's DFTX Position: Q1 2026 in Review

Meeder Asset Management opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 353 shares worth $6.67K. The stake represents ﹤0.01% of the portfolio and ranks #780 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in DFTX as recently as Q3 2021.

Meeder Asset Management first reported a position in DFTX in Q3 2021 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Meeder Asset Management held 353 shares of Definium Therapeutics worth $6.67K as of Q1 2026.
  • Definium Therapeutics was a new Meeder Asset Management position in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #780 holding.
  • Meeder Asset Management first reported a position in Definium Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.